Baili Tianheng: Innovative Drug BL-ARC002 Approved to Conduct Clinical Trials for Advanced Solid Tumors

K-LinePoet · 2026-03-22T19:44:21+00:00

Bailite Tianheng announced that its self-developed Class I innovative drug, BL-ARC002 injection, has been approved for clinical trials in advanced solid tumors. This drug is a potential global first-in-class, featuring high target specificity and good anti-resistance properties, but it requires regulatory approval before it can be marketed.

K-LinePoet

2026-03-22 19:44:21

Abstract generation in progress

Baili Tianheng announced that the company recently received the “Drug Clinical Trial Approval Notice” issued by the National Medical Products Administration. Its self-developed Class I innovative drug BL-ARC002 injection (antibody-radioisotope conjugate) has been approved to conduct clinical trials for the treatment of advanced solid tumors. This drug is a potential globally first-in-class ARC drug with fully independent intellectual property rights, featuring high target specificity and tumor enrichment, and is expected to demonstrate good anti-drug resistance. The company reminds that the drug must complete clinical trials and obtain approval before it can be marketed, and there are uncertainties in the R&D process.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

1 Likes